MARKET WIREReuters • 3h ago
Iran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz - ReutersIran's IRGC Navy says two tankers 'exploded' after hitting mines in Hormuz Reuters
Why ABUS Stock slipped -0.93% Today — RQD Quant Desk Flash
$4.28 -0.93% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $4.26
Arbutus Biopharma Corporation (ABUS) carries a Roarable Rating of E (Strong Sell) with 22/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE E • RED ALERT
Cap $656.0M
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $4.26 (-0.36%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 3/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (22/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-11.4% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERRED ALERT • E
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk E
Each axis scored 0–20
12M PRICE TARGET CONE-16.1% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for ABUS)Realized 20D OHLCV Swing Band: ±8.2%
Deterministic 5-Pillar Attribution (22/100 Composite)
🔍 WHY ABUS SCORES 22/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+6/20 pts (27% of score)
20D Institutional Volume Accumulation (±8.2% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (27% of score)
FRED Regime × Technicals: 40% of 52W Range • RSI-14 at 39.9 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade E$4.22+0% Next Q
15
Q2 (-2Q)Grade E$4.22-0.5% Next Q
17
Q3 (-1Q)Grade E$4.20+1.9% Next Q
19
CurrentGrade E$4.28-11.4% Hist 90D α
22
Trajectory: E (15) → E (22)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a ABUS Turnaround Squeeze
While ABUS currently carries a cautious 22/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.71) and Max Pain ($4.49) forces dealer call-delta covering toward $5.72.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $ABUS• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “ABUS Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why ABUS Stock slipped -0.93% Today — RQD Quant Desk Flash
Arbutus Biopharma Corporation (ABUS) slipped -0.93% to $4.28, trading at 40% of its 52-week range ($3.5 – $5.45). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 40% of its 52-week range ($3.5 – $5.45) with RSI-14 at 39.9 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±8.2% around $4.28 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable E (Strong Sell) backed by 52% gross margin and $0 annual free cash flow.
Live ABUS Headlines & Catalysts
MARKET WIRECNBC • 5h ago
Here are 3 big things we're watching in the stock market in the week aheadThe market could use a few victories in the days ahead, which will be filled with more earnings, an election, and jobs data.
MARKET WIRECNBC • 5h ago
Democratic Rep. Stevens endorses Rogers over El-Sayed in Michigan Senate electionHaley Stevens had lost the Democratic nomination for Senate in Michigan to Abdul El-Sayed earlier this year.
RISK WATCHReuters • 6h ago
Israeli strikes kill eight people in Gaza - medics say - ReutersIsraeli strikes kill eight people in Gaza - medics say Reuters
MARKET WIREReuters • 8h ago
Russia's FSB says minor detained over park attack threat after US tip-off - ReutersRussia's FSB says minor detained over park attack threat after US tip-off Reuters
MARKET WIREReuters • 8h ago
Iran, Qatari mediators hold third day of talks to end US-Iran war - ReutersIran, Qatari mediators hold third day of talks to end US-Iran war Reuters
CATALYSTReuters • 9h ago
Qatar surges, bucking Gulf market slide on Iran war concerns - ReutersQatar surges, bucking Gulf market slide on Iran war concerns Reuters
MARKET WIREReuters • 10h ago
OPEC+ keeps December oil output targets steady ahead of tougher call for 2027 - ReutersOPEC+ keeps December oil output targets steady ahead of tougher call for 2027 Reuters
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ABUS)
- ✓Walkthrough of ABUS's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ABUS // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.90%📐 HORIZONTAL RANGE
2026-10-30O $4.28H $4.30L $4.14C $4.28VOL 2.53M
RES: $5.56SUP: $4.01SMA50: $4.71SMA200: $4.50
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
ABUS Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +128.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on ABUS today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for ABUS. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ABUS today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ABUS)
Health Care Rank #1003 of 1016
⚔️ LXRX vs ABUS Full Matrix →
1. Head-to-Head Health Care Peer Comparison (ABUS vs. LXRX, IMMX, ANL, BCAX)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, Arbutus Biopharma Corporation (ABUS) ranks #1003 by composite RQD confidence (22/100, grade E) and #410 by equity capitalization ($656.0M). Within this direct 5-issuer industry benchmark cohort, ABUS leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. ANL currently holds the highest overall quantitative score in the immediate peer group at 52/100 (D+) compared with ABUS at 22/100 (E).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| ABUS
ACTIVE
Arbutus Biopharma Corporation | E | 22/100 | — | — | -35.0% | -0.93% | $656.0M | Benchmark Subject |
| LXRX Lexicon Pharmaceuticals Inc. | D- | 39/100 | — | 96.0% | -31.5% | -0.34% | $658.5M | /lxrx-vs-abus → |
| IMMX Immix Biopharma Inc. | E | 33/100 | — | — | -35.0% | -1.78% | $661.6M | /immx-vs-abus → |
| ANL Adlai Nortye Group Ltd. | D+ | 52/100 | — | — | — | +0.78% | $662.0M | /anl-vs-abus → |
| BCAX Bicara Therapeutics Inc. | D | 45/100 | — | — | -35.0% | -0.31% | $643.9M | /bcax-vs-abus → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001447028In its most recent audited fiscal period (FY2025, filed 2025-12-31), Arbutus Biopharma Corporation (ABUS) reported GAAP revenue of $14.1M (+128.2% vs. FY2024 revenue of $6.2M , and -22.4% cumulative change since FY2023) , GAAP net income of -$33.5M, operating cash flow of -$39.6M, and free cash flow of -$39.6M (+39.1% YoY). On the balance sheet, ABUS closed FY2025 with $94.6M in total assets against $0 in total debt (Altman Z-Score: 1.34, Piotroski F-Score: 3/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $14.1M | -$33.5M | -$39.6M | -$39.6M | $94.6M | — |
| FY2024 (FY) | 2024-12-31 | $6.2M | -$69.9M | -$64.8M | -$65.0M | $131.7M | — |
| FY2023 (FY) | 2023-12-31 | $18.1M | -$72.8M | -$85.9M | -$85.9M | — | — |
3. ABUS Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs ABUS stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, Arbutus Biopharma Corporation (NASDAQ: ABUS) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 22/100 at a spot price of $4.28 (-0.93% 1D, market cap $656.0M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 5/20, FRED Macro Regime Fit 6/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ABUS ranks #1003 in composite RQD confidence.
How does ABUS compare to LXRX and IMMX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), ABUS carries a Roarable E (22/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LXRX (Lexicon Pharmaceuticals Inc.) holds a D- grade (39/100 RQD, P/E N/A, ROIC -31.5%, cap $658.5M) and IMMX (Immix Biopharma Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $661.6M). Among the 5-stock peer group, ABUS leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).
What are the biggest fundamental strengths and SEC risk factors for ABUS?
Per ABUS's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001447028), Arbutus Biopharma Corporation generated $14.1M in revenue (+128.2% YoY), -$33.5M in net income, and -$39.6M in free cash flow against $94.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is ABUS trading relative to its 50-day, 200-day, and 52-week technical levels?
ABUS last traded at $4.28 (-0.93% on volume of 1,209,756 shares), positioning the stock -9.13% below its 50-day simple moving average ($4.71) and -4.89% below its 200-day simple moving average ($4.50). Across its 52-week range of $3.50 to $5.45, ABUS sits at the 40.0% percentile with a 14-day RSI of 39.9 (NEUTRAL RANGE) and an implied next-earnings move of ±8.2% ($3.93 to $4.63).
ABUS Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is ABUS stock moving today?
Why ABUS Stock slipped -0.93% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.